While the GW Pharmaceuticals platform adds significant value, an investment in Jazz Pharmaceuticals carries its own risks. The company took on substantial debt to finance the $7.2 billion acquisition, leading to a temporary increase in leverage. Potential investors should monitor the company's progress in paying down this debt and the continued clinical trial success of its pipeline.
GW Pharmaceuticals pioneered the use of cannabis-derived medicines, most notably . Since the acquisition, this platform has become a cornerstone of the Jazz Pharmaceuticals business model. buy stock in gw pharmaceuticals
: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology. The combined company now has a robust portfolio
Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) most notably . Since the acquisition
To invest in the GW Pharmaceuticals portfolio today, you would need to buy shares of its parent company, .
If you are looking to buy stock in , it is important to know that as of April 28, 2026, the company no longer trades under its own ticker symbol. It was fully acquired by Jazz Pharmaceuticals in May 2021 for approximately $7.2 billion.